Amneal Pharmaceuticals, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 2.09B | 2.21B | 2.39B | 2.79B | 3.02B | 8.0% | |
| Cost of Revenue | (1.32B) | (1.42B) | (1.53B) | (1.77B) | (1.88B) | 6.2% | |
Gross Profit | 768.97M | 791.46M | 863.87M | 1.02B | 1.14B | 11.3% | |
| Operating Expenses | |||||||
| Research & Development | (209.56M) | (208.66M) | (194.75M) | (190.71M) | (186.18M) | -2.4% | |
| Selling, General & Administrative | (365.50M) | (399.70M) | (429.68M) | (476.44M) | (526.83M) | 10.6% | |
| Depreciation & Amortization | (233.41M) | (240.18M) | (229.40M) | (236.19M) | (223.57M) | -5.3% | |
Operating Income (EBIT) | 152.72M | -94.93M | 204.37M | 249.33M | 423.09M | 69.7% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | (136.32M) | (158.38M) | (210.63M) | (258.60M) | (241.09M) | -6.8% | |
| Other Income/Expenses (Net) | -121.35M | -153.20M | -244.64M | -304.34M | -283.88M | -6.7% | |
Income Before Tax | 31.37M | -248.13M | -40.27M | -55.01M | 139.21M | -353.0% | |
| Income Tax Expense | (11.20M) | (6.66M) | (8.45M) | (18.86M) | (11.28M) | -40.2% | |
Net Income | 10.62M | -129.99M | -83.99M | -116.89M | 72.06M | -161.6% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $0 | $-1 | $-0 | $-0 | $0 | -160.5% | |
| Weighted Avg Shares Outstanding | 148.92M | 150.94M | 174.99M | 308.98M | 313.37M | 1.4% | |
| Weighted Avg Shares Outstanding (Diluted) | 151.82M | 150.94M | 176.14M | 308.98M | 324.81M | 5.1% | |
EBITDA | 401.10M | 440.21M | 500.78M | 439.77M | 603.87M | 37.3% |
Explore AMRX
AMRX in the Healthcare
Mid Cap